Literature DB >> 4441566

[Characteristics of galanthamine as a reversible inhibitor of cholinesterase].

E T Vasilenko, V D Tonkopiĭ.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4441566

Source DB:  PubMed          Journal:  Biokhimiia        ISSN: 0320-9725


× No keyword cloud information.
  5 in total

1.  Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group.

Authors:  G K Wilcock; S Lilienfeld; E Gaens
Journal:  BMJ       Date:  2000-12-09

Review 2.  Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease.

Authors:  Krista L Lanctôt; Nathan Herrmann; Maysoon M LouLou
Journal:  J Psychiatry Neurosci       Date:  2003-01       Impact factor: 6.186

3.  Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.

Authors:  K Rockwood; J Mintzer; L Truyen; T Wessel; D Wilkinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-11       Impact factor: 10.154

4.  Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen.

Authors:  N Thavichachart; K Phanthumchinda; S Chankrachang; R Praditsuwan; S Nidhinandana; V Senanarong; N Poungvarin
Journal:  Int J Clin Pract       Date:  2006-05       Impact factor: 2.503

Review 5.  The case of galantamine: repurposing and late blooming of a cholinergic drug.

Authors:  Hermann Am Mucke
Journal:  Future Sci OA       Date:  2015-09-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.